Joy Sun

Joy Sun Cooper is the Head of Commercialization and Patient Access at MAPS Public Benefit Corporation (MAPS PBC), which was recently renamed to Lykos Therapeutics.5 In this role, she is responsible for leading efforts to make MDMA-assisted therapy accessible to patients, particularly for the treatment of PTSD.1 2

Background and Experience

Before joining MAPS PBC, Joy Sun Cooper had a diverse career in healthcare and social impact:

She co-founded and served as Chief Operating Officer of Groups, a venture-backed healthcare services company focused on treating opioid use disorder in rural America.1
She helped launch GiveDirectly, a global nonprofit that provides direct cash transfers to people living in extreme poverty.1
She worked as an engagement manager at McKinsey & Company in the healthcare and agriculture practices.1
She served as Director of Operations at the Clinton Health Access Initiative (CHAI), where she designed and implemented large-scale HIV treatment programs in Sub-Saharan Africa.1

Role at MAPS PBC (now Lykos Therapeutics)

At MAPS PBC, Joy Sun Cooper plays a crucial role in:

Commercialization strategy: She is involved in developing pricing models and strategies for MDMA-assisted therapy.2
Patient access: She works on ensuring equitable access to MDMA therapy, including through patient assistance programs.3
Regulatory affairs: She is part of the team working on the FDA approval process for MDMA-assisted therapy.4
Scaling operations: Cooper is involved in plans to train 30,000 practitioners to reach 1 million PTSD patients by 2031.2

Recent Developments

Joy Sun Cooper has been involved in several significant milestones for MAPS PBC:

In December 2023, she was part of the team that submitted a new drug application to the FDA for MDMA-assisted therapy for PTSD, marking the first NDA submission for any psychedelic-assisted therapy.4
In January 2024, she announced the company's name change from MAPS PBC to Lykos Therapeutics, reflecting the evolution of the organization.5

Joy Sun Cooper's work at MAPS PBC (now Lykos Therapeutics) is focused on bridging the gap between clinical research and patient access, with the goal of making MDMA-assisted therapy a widely available treatment option for those suffering from PTSD.